From our August 2019 Newsletter

News

Here are a few items that address the exciting news about the FDA approval of pretomanid in the BPaL regimen; describe concern about the standard of the research that led to its approval, the regulatory precedent it sets; and highlight uncertainty around its affordability and access.

1. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
2. New tuberculosis medicine studied in South Africa approved in United States
3. New Drug Could Be Game Changer For Drug-Resistant TB. But A Question Looms